358 related articles for article (PubMed ID: 26360791)
21. Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
Arcaini L; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Cabeçadas J; Campo E; Pileri SA; Biyukov T; Patturajan M; Casadebaig Bravo ML; Trnĕný M;
Br J Haematol; 2018 Jan; 180(2):224-235. PubMed ID: 29193019
[TBL] [Abstract][Full Text] [Related]
22. Role of allogeneic stem cell transplantation in mantle cell lymphoma.
Cohen JB; Burns LJ; Bachanova V
Eur J Haematol; 2015 Apr; 94(4):290-7. PubMed ID: 25154430
[TBL] [Abstract][Full Text] [Related]
23. [Mantle cell lymphoma: Towards a personalized therapeutic strategy?].
Navarro Matilla B; García-Marco JA
Med Clin (Barc); 2015 Jun; 144(12):553-9. PubMed ID: 25023849
[TBL] [Abstract][Full Text] [Related]
24. Ibrutinib for mantle cell lymphoma.
Tucker DL; Rule SA
Future Oncol; 2016 Feb; 12(4):477-91. PubMed ID: 26759179
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.
Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
Cancer Med; 2019 Nov; 8(16):6860-6870. PubMed ID: 31560165
[TBL] [Abstract][Full Text] [Related]
26. Mantle Cell Lymphoma.
Cheah CY; Seymour JF; Wang ML
J Clin Oncol; 2016 Apr; 34(11):1256-69. PubMed ID: 26755518
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide for the treatment of mantle cell lymphoma.
Morabito F; Skafi M; Recchia AG; Kashkeesh A; Hindiyeh M; Sabatleen A; Morabito L; Alijanazreh H; Hamamreh Y; Gentile M
Expert Opin Pharmacother; 2019 Apr; 20(5):487-494. PubMed ID: 30608891
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Prescrire Int; 2016 Apr; 25(170):91. PubMed ID: 27186618
[No Abstract] [Full Text] [Related]
29. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Bond DA; Alinari L; Maddocks K
Clin Adv Hematol Oncol; 2019 Apr; 17(4):223-233. PubMed ID: 31188814
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
31. [Treatment for mantle cell lymphoma].
Izutsu K
Rinsho Ketsueki; 2017; 58(10):2026-2032. PubMed ID: 28978845
[TBL] [Abstract][Full Text] [Related]
32. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
Avivi I; Goy A
Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
[TBL] [Abstract][Full Text] [Related]
33. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
Jerkeman M; Eskelund CW; Hutchings M; Räty R; Wader KF; Laurell A; Toldbod H; Pedersen LB; Niemann CU; Dahl C; Kuitunen H; Geisler CH; Grønbæk K; Kolstad A
Lancet Haematol; 2018 Mar; 5(3):e109-e116. PubMed ID: 29396091
[TBL] [Abstract][Full Text] [Related]
34. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.
Nazeef M; Kahl BS
Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443
[TBL] [Abstract][Full Text] [Related]
35. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
Witzig TE; Luigi Zinzani P; Habermann TM; Tuscano JM; Drach J; Ramchandren R; Kalayoglu Besisik S; Takeshita K; Casadebaig Bravo ML; Zhang L; Fu T; Goy A
Am J Hematol; 2017 Oct; 92(10):E575-E583. PubMed ID: 28699256
[TBL] [Abstract][Full Text] [Related]
36. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
Atilla E; Atilla PA; Demirer T
Int J Hematol; 2017 Mar; 105(3):257-264. PubMed ID: 27995456
[TBL] [Abstract][Full Text] [Related]
37. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
Owen C; Berinstein NL; Christofides A; Sehn LH
Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
[TBL] [Abstract][Full Text] [Related]
38. Activity of thalidomide and lenalidomide in mantle cell lymphoma.
Richardson SJ; Eve HE; Copplestone JA; Dyer MJ; Rule SA
Acta Haematol; 2010; 123(1):21-9. PubMed ID: 19907157
[TBL] [Abstract][Full Text] [Related]
39. [Mantle Cell Lymphoma - Cutting edge Dia-gnostics and Treatment Approaches].
Klener P; Trněný M
Klin Onkol; 2015; 28 Suppl 3():3S80-6. PubMed ID: 26489506
[TBL] [Abstract][Full Text] [Related]
40. Current regimens and novel agents for mantle cell lymphoma.
Chen Y; Wang M; Romaguera J
Br J Haematol; 2014 Oct; 167(1):3-18. PubMed ID: 24974852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
